Biomedical subjects

R L Hill-Zobel

Publications and source records attributed to R L Hill-Zobel.

6 recordsLinked to original sources

PubMed1987

Should platelets be radiolabelled in plasma medium?

Because of the low labelling efficiency of platelets with In-111 oxine in plasma containing media, most investigators have labelled platelets in plasma-free media. However, labelling of platelets with In-111 oxine in plasma-free media may result in either: irreversible damage leading to rapid clearance from the circulation and permanent hepatic sequestration; or reversible damage with transient hepatic sequestration without affecting the in vivo survival. Since human platelets can be labelled with In-111 oxine in plasma in sufficient efficiency for routine clinical use, they should be labelled in plasma whenever possible. The use of newer In-111 chelates, tropolone and mercaptopyridine-N-oxide, which label platelets with high efficiency in plasma as well as in plasma-free media, may offer another alternative.

Animals↗

PubMed1987

Effects of chelates and incubation media on platelet labeling with indium-111.

We studied the effects of various [111In]chelates and incubation media on labeling efficiency (LE) and in vivo survival of platelets. High LE of human and rabbit platelets in plasma were obtained with [111In]tropolone and [111In]mercaptopyridine-N-oxide. Indium-111 oxine in plasma resulted in a moderate LE and required a longer incubation time, while [111In]oxine sulfate had low LE and inconsistent labeling. High LE for all forms of [111In]chelates were achieved in labeling media free of plasma. However, in vivo platelet survival in rabbits was markedly reduced when platelets were labeled in the absence of plasma.

Animals↗

PubMed1986

Organ distribution and fate of human platelets: studies of asplenic and splenomegalic patients.

Little is known about the organ distribution and fate of human platelets. We investigated the kinetics, organ distribution, and fate of autologous 111In-oxine-labeled platelets in 12 normal volunteers, four asplenic subjects, and four patients with splenomegaly. The initial recovery of infused 111In-platelets from the circulation was 97.8 +/- 9.8% (means +/- SD) for asplenic subjects and 26.3 +/- 5.9% for splenomegalic patients as compared to 59.2 +/- 9.3% for normal controls. The mean platelet survival times as derived from the multiple-hit model were 9.2 +/- 1.0 days for asplenics and 6.2 +/- 0.6 days for splenomegalic subjects (8.4 +/- 0.8 days for normals). At 30 min postinfusion, 79.4 +/- 19.2% of the infused 111In-platelets pooled in the spleen of splenomegalic subjects and 42.7 +/- 12.2% in normal controls. There was 7.1 +/- 2.0, 12.6 +/- 3.7, and 29.3 +/- 8.4% pooling in the liver of splenomegalic, normal, and asplenic subjects, respectively. At 10 days postinfusion, 37 and 24% of the 111In-platelets were sequestered in the spleen and liver of normal control subjects, respectively. Similar figures for splenomegalic subjects were 71 and 14%, respectively. In asplenic subjects, 89% was sequestered in the liver. We conclude that spleen and liver are the primary sites of platelet destruction, accounting for 61% of infused 111In-platelets in normal volunteers and 85% in splenomegalics, while the liver is the primary site of platelet destruction, accounting for 89% in asplenic subjects.

Aged↗

PubMed1983

Evaluation of arterial injury due to balloon angioplasty by 111In-labelled platelets.

The sensitivity of 111In-labelled platelets for the detection of intimal trauma following balloon angioplasty was evaluated in 8 arteries in 6 patients. Focal platelet accumulation was detected at all 3 iliacs, one superficial femoral and the anterior tibial artery angioplasty sites. Minimal platelet accumulation was present at the superficial femoral artery angioplasty site in another patient whereas in both renal arteries no focal platelet accumulation was detectable. These results indicate that 111In-labelled platelets may provide a sensitive method for evaluation platelet accumulation at the balloon angioplasty site in the peripheral circulation.

Angioplasty, Balloon↗

PubMed1983

111In oxine-labeled rabbit platelets: in vivo distribution and sites of destruction.

We have studied the kinetics, biodistribution, and fate of autologous platelets labeled with 111In-oxine in rabbits. The initial recovery was 75% and mean survival time was 2.8 days when the data were analyzed by the multiple-hit gamma function model. Using a modified geometric mean for correction of attenuation, there was good correlation between the values obtained by in vivo quantification and those obtained by postmortem measurements of the radioactivity in the liver and the spleen (i.e., r = 0.854 and 0.899, respectively, n = 32). Using this method, it was shown that after infusion, the 111In-platelets rapidly accumulated in these two organs reaching 35% and 12% of the injected dose in the liver and spleen, respectively, by 1 day. Thereafter, there was little subsequent change. On the sixth day, when essentially all of the 111In-platelets had cleared from the circulation, a total of 82% of the injected dose was deposited in the three major reticuloendothelial organs: liver (40%), spleen (14%), and bone marrow (28%). Our results suggest that in addition to liver and spleen, bone marrow played an important role in sequestering platelets in rabbits.

Animals↗

PubMed1982

Kinetics and distribution of 111Indium-labeled platelets in patients with homocystinuria.

Homocystinuria is an inborn error of metabolism involving a high incidence of thromboembolism. It sometimes improves with large doses of pyridoxine. We investigated the kinetics and distribution of 111Indoxine-labeled platelets in 11 normal volunteers and 12 patients with homocystinuria, none of whom had clinical evidence of acute thrombosis at the time of the study. Six of the patients were resistant to pyridoxine and had homocystinemia. There were no statistical differences in mean platelet-survival times between pyridoxine responders and nonresponders or between normal subjects and pyridoxine responders or nonresponders, regardless of whether a linear, exponential, or multiple-hit model was used to analyze the kinetic data. Plasma homocystine levels had no apparent effect on mean platelet-survival time. There was no abnormal accumulation of platelets in any of the patients, and the distribution of platelets in liver and spleen was similar to that in normal subjects. Our results suggest that the kinetics and distribution of platelets in patients with homocystinuria who have no clinical evidence of thromboembolism are normal. Thus, the data do not provide evidence for disordered platelet function or for an ongoing interaction of platelets with vessel walls in this condition.

Adolescent↗